The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Novel Role of Follistatin, an Activin-binding Protein, in the Inhibition of Activin Action in Rat Pituitary Cells
Open accessAbstract
There are two types of the activin-binding protein follistatin (FS), FS-288 and FS-315. These result from alternative splicing of mRNA. FS-288 exhibits high affinity for cell-surface heparan sulfate proteoglycans, whereas FS-315 shows low affinity. To understand the physiological role of cell-associated FS, we investigated the binding of activin to cell-associated FS and its behavior on the cell surface using primary cultured rat pituitary cells. Affinity cross-linking experiments using 125I-activin A demonstrated that activin bound to rat pituitary cells via FS as well as to their receptors on the cell surface. FS-288 promoted the binding of activin A to the cell surface more markedly than FS-315. When the cells were incubated with 125I-activin A in the presence of FS-288, significant degradation of activin A was observed, and this was dependent on the FS-288 concentration. This activin degradation was abolished by heparan sulfate, chloroquine, and several lysosomal enzyme inhibitors. Moreover, FS-288 stimulated cellular uptake of activin A, whereas chloroquine suppressed lysosomal degradation following internalization, as demonstrated by microscopic autoradiography. These results suggest that cell-associated FS-288 accelerates the uptake of activin A into pituitary cells, leading to increased degradation by lysosomal enzymes, and thus plays a role in the activin clearance system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90512-w · Cited by 2,440
Primary structure of the human follistatin precursor and its genomic organization
Shimasaki, S., Koga, M., Esch, F., Cooksey, K., Mercado, M., Koba, A., Ueno, N., Ying, S. Y., Ling, N., & Guillemin, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4218 · Cited by 232
Self-citation
Cited by
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
Pathway for Polyarginine Entry into Mammalian Cells
Fuchs, S. M., & Raines, R. T. (2004) · Biochemistry · doi:10.1021/bi035933x · Cited by 374
Welt, C., Sidis, Y., Keutmann, H., & Schneyer, A. (2002) · Experimental Biology and Medicine · doi:10.1177/153537020222700905 · Cited by 324
Activins and Inhibins: Roles in Development, Physiology, and Disease
Namwanje, M., & Brown, C. W. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021881 · Cited by 294
“4B), and in part explains the different bioactivities for the follistatin isoforms (Sugino et al. 1993; Hashimoto et al. 1997).”
Follistatin: A Multifunctional Regulatory Protein
Phillips, D. J., & de Kretser, D. M. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0169 · Cited by 275
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.
Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244
Inhibins, activins and follistatin in reproduction
de Kretser, D. M. (2002) · Human Reproduction Update · doi:10.1093/humupd/8.6.529 · Cited by 211
“The biological importance of the released follistatin and activin remains unclear, especially in view of studies suggesting that the binding of activin to follistatin targets activin to a lysosomal intracellular degradation pathway (Hashimoto et al., 1997).”
Sidis, Y., Mukherjee, A., Keutmann, H., Delbaere, A., Sadatsuki, M., & Schneyer, A. (2006) · Endocrinology · doi:10.1210/en.2006-0089 · Cited by 211
TGF-β family co-receptor function and signaling
Nickel, J., Ten Dijke, P., & Mueller, T. D. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx126 · Cited by 198
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
Rodino‐Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K., & Mendell, J. R. (2009) · Muscle & Nerve · doi:10.1002/mus.21244 · Cited by 194
cDNA cloning and expression of human activin βE subunit
Hashimoto, O., Tsuchida, K., Ushiro, Y., Hosoi, Y., Hoshi, N., Sugino, H., & Hasegawa, Y. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00157-0 · Cited by 54
Clinical and therapeutic implications of follistatin in solid tumours
SHI, L., RESAUL, J., OWEN, S., YE, L., & JIANG, W. G. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20005 · Cited by 47
de Kretser, D. M., Bensley, J. G., Pettilä, V., Linko, R., Hedger, M. P., Hayward, S., Allan, C. A., McLachlan, R. I., Ludlow, H., & Phillips, D. J. (2013) · Critical Care · doi:10.1186/cc13093 · Cited by 39
“Proof that these elevated activin A levels caused death emerged from halving the LPSinduced mortality by the administration of follistatin, which binds activin A virtually irreversibly and targets the complex to a lysosomal degradation pathway [12,13,46].”
Background
Metadata
- Authors
- Hashimoto, O., Nakamura, T., Shoji, H., Shimasaki, S., Hayashi, Y., & Sugino, H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-05
- Volume
- 272
- Issue
- 21
- Pages
- 13835-13842
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2036453314
- Cited by
- 186
- References
- 2
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.